Cover Image

Local amphotericin B therapy for Cutaneous Leishmaniasis: A systematic review.

<h4>Background</h4>Cutaneous leishmaniasis (CL) is characterized by potentially disfiguring skin ulcers carrying significant social stigma. To mitigate systemic drug exposure and reduce the toxicity from available treatments, studies addressing new local therapeutic strategies using avai...

Full description

Saved in:

Bibliographic Details
Main Authors:	Líndicy Leidicy Alves (Author), Mariana Lourenço Freire (Author), Isadora Lana Troian (Author), Eliane de Morais-Teixeira (Author), Gláucia Cota (Author)
Format:	Book
Published:	Public Library of Science (PLoS), 2024-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The cure rate after different treatments for mucosal leishmaniasis in the Americas: A systematic review.
by: Janaína de Pina Carvalho, et al.
Published: (2022)

Efficacy of intralesional amphotericin B for the treatment of cutaneous leishmaniasis
by: Vahid Mashayekhi Goyonlo, et al.
Published: (2014)

Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea.
by: Romain Guery, et al.
Published: (2017)

Co-delivery of amphotericin B and pentamidine loaded niosomal gel for the treatment of Cutaneous leishmaniasis
by: Adnan Anjum, et al.
Published: (2023)

Formulation of Amphotericin B in PEGylated Liposomes for Improved Treatment of Cutaneous Leishmaniasis by Parenteral and Oral Routes
by: Guilherme S. Ramos, et al.
Published: (2022)

Single-dose liposomal amphotericin B for visceral leishmaniasis
by: Nilima A Kshirsagar
Published: (2014)

Different liposomal amphotericin B formulations for visceral leishmaniasis
by: Thomas P C Dorlo, et al.
Published: (2014)

Antimony to Cure Visceral Leishmaniasis Unresponsive to Liposomal Amphotericin B.
by: Gloria Morizot, et al.
Published: (2016)

Comparison of efficacy of two different concentrations of intralesional amphotericin B in the treatment of cutaneous leishmaniasis; A randomized controlled trial
by: Pooja Goswami, et al.
Published: (2019)

Different liposomal amphotericin B formulations for visceral leishmaniasis-Author's reply
by: Nilima Kshirsagar
Published: (2014)

Single-dose liposomal amphotericin B: an effective treatment for visceral leishmaniasis
by: Prabhat Kumar Sinha, et al.
Published: (2014)

Topical Amphotericin B Semisolid Dosage Form for Cutaneous Leishmaniasis: Physicochemical Characterization, Ex Vivo Skin Permeation and Biological Activity
by: Diana Berenguer, et al.
Published: (2020)

Safety Evaluation of Nano-Liposomal Formulation of Amphotericin B (SinaAmpholeish) in Animal Model as a Candidate for Treatment of Cutaneous Leishmaniasis
by: Seyed Ebrahim Eskandari, et al.
Published: (2018)

A phase II study to evaluate the safety and efficacy of topical 3% amphotericin B cream (Anfoleish) for the treatment of uncomplicated cutaneous leishmaniasis in Colombia.
by: Liliana López, et al.
Published: (2018)

Transcriptional blood signatures for active and amphotericin B treated visceral leishmaniasis in India.
by: Michaela Fakiola, et al.
Published: (2019)

Pharmacokinetic / pharmacodynamic relationships of liposomal amphotericin B and miltefosine in experimental visceral leishmaniasis.
by: Andrew A Voak, et al.
Published: (2021)

Economic impact of localized cutaneous leishmaniasis on adult patients of a referral service in Belo Horizonte, Minas Gerais State, Brazil
by: Endi Lanza Galvão, et al.
Published: (2020)

Cost-effectiveness of serological tests for human visceral leishmaniasis in the Brazilian scenario.
by: Mariana Lourenço Freire, et al.
Published: (2020)

Performance of serological tests available in Brazil for the diagnosis of human visceral leishmaniasis.
by: Mariana Lourenço Freire, et al.
Published: (2019)

Amphotericin-B in dermatology
by: Akash Agarwal, et al.
Published: (2022)

Liposomal Amphotericin B for Treatment of Leishmaniasis: From the Identification of Critical Physicochemical Attributes to the Design of Effective Topical and Oral Formulations
by: Frédéric Frézard, et al.
Published: (2022)

Characterization and evaluation of amine-modified graphene amphotericin B for the treatment of visceral leishmaniasis: in vivo and in vitro studies
by: Mudavath SL, et al.
Published: (2014)

Visceral Leishmaniasis in Children in Southern Turkey: Evaluation of Clinical and Laboratory Findings and Liposomal Amphotericin B Treatment
by: Barbaros Şahin Karagün, et al.
Published: (2019)

Amphotericin B-Induced Encephalopathy
by: J Gordon Millichap
Published: (1995)

Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India.
by: Sakib Burza, et al.
Published: (2014)

Mutilating localized cutaneous leishmaniasis caused by Leishmania guyanensis
by: Dina Fabrício da Silva, et al.
Published: (2023)

Cost-effectiveness study of therapeutic approaches for mucosal leishmaniasis
by: Janaína de Pina Carvalho, et al.
Published: (2024)

Design of amphotericin B oral formulation for antifungal therapy
by: Min Liu, et al.
Published: (2017)

Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy
by: Célia Faustino, et al.
Published: (2020)

Effectiveness and safety of short course liposomal amphotericin B (AmBisome) as first line treatment for visceral leishmaniasis in Bangladesh.
by: Emiliano Lucero, et al.
Published: (2015)

Intralesional infiltration versus parenteral use of meglumine antimoniate for treatment of cutaneous leishmaniasis: A cost-effectiveness analysis.
by: Nayara C Brito, et al.
Published: (2019)

Amphotericin B lipid complex: treatment of invasive fungal infections in patients refractory to or intolerant of amphotericin B deoxycholate
by: PH Chandrasekar
Published: (2008)

Tin tack sign in localized cutaneous leishmaniasis: Reader's question
by: Ayda Acar
Published: (2020)

Concomitant visceral and localized cutaneous leishmaniasis in two Moroccan infants
by: Tarik Mouttaki, et al.
Published: (2018)

Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome).
by: Sakib Burza, et al.
Published: (2014)

Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: a randomized, open-label study.
by: Shyam Sundar, et al.
Published: (2014)

Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study
by: Dr. Dinesh Mondal, PhD, et al.
Published: (2014)

A Rare Skin Lesion During Pregnancy: Localized Cutaneous Leishmaniasis
by: Cihan Çetin, et al.
Published: (2016)

Local increase of arginase activity in lesions of patients with cutaneous leishmaniasis in Ethiopia.
by: Tamrat Abebe, et al.
Published: (2012)

Harmonized clinical trial methodologies for localized cutaneous leishmaniasis and potential for extensive network with capacities for clinical evaluation.
by: Piero Olliaro, et al.
Published: (2018)